Published in final edited form as:

Curr Opin Neurobiol. 2014 August ; 0: 53–60. doi:10.1016/j.conb.2014.02.011.

Nogo limits neural plasticity and recovery from injury

Martin E. Schwab¹ and Stephen M. Strittmatter²

¹Brain Research Institute, University of Zurich, Winterthurerstr.190, CH-8057 Zurich, Switzerland

²Department of Neurology, and Interdepartmental Program in Cellular Neuroscience, Neurodegeneration, and Repair (CNNR), Yale University School of Medicine, BCM 436, 295 Congress Avenue, New Haven, Connecticut 06510, USA

Abstract

The expression of Nogo-A and the receptor NgR1 limit the recovery of adult mammals from central nervous system injury. Multiple studies have demonstrated efficacy from targeting this pathway for functional recovery and neural repair after spinal cord trauma, ischemic stroke, optic nerve injury and models of multiple sclerosis. Recent molecular studies have added S1PR2 as a receptor for the amino terminal domain of Nogo-A, and have demonstrated shared components for Nogo-A and CSPG signalling as well as novel Nogo antagonists. It has been recognized that neural repair involves plasticity, sprouting and regeneration. A physiologic role for Nogo-A and NgR1 has been documented in the restriction of experience-dependent plasticity with maturity, and the stability of synaptic, dendritic and axonal anatomy.

Introduction

The longitudinal growth of nerve fibers, the regeneration of injured axons and the structural plasticity of axons and dendrites are confined to very short distances and limited spatial dimensions in the adult mammalian central system (CNS). The successful regeneration of adult CNS axons of multiple origins into peripheral nerve grafts placed into spinal cord, brain or optic nerve over centimeter distances emphasized the key role of factors from the local tissue microenvironment in determining the extent of growth [1]. Twenty years ago, specific neurite growth inhibitory factors, many of which were enriched in myelin, were discovered. Nogo-A, the myelin proteins, MAG and OMgp, several semaphorins and ephrins as well as chondroitin sulphate proteoglycans have been identified [2]. For many of these molecules the detailed expression pattern in the adult CNS, the possible interplay between single factors, as well as their *in vivo* roles in the intact or injured adult CNS are not well characterized yet. More information is available for the membrane protein Nogo-A;

© 2014 Elsevier Ltd. All rights reserved.

Correspondence: Address either M.E.S. (schwab@hifo.uzh.ch) or S.M.S. (stephen.strittmatter@yale.edu).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest: S.M.S. is a co-founder of Axerion Therapeutics, seeking to develop NgR- and PrP-based therapeutics.

some key concepts and the most recent literature on Nogo-A will be summarized in this short review.

Nogo-A interacts with a multisubunit receptor complex

Fragment analyses and binding studies showed that the 1200 aa protein Nogo-A contains more than one growth inhibiting domain. The 66 aa extracellular loop between the two C-terminal intramembrane segments binds to a GPI-linked, LRR-containing membrane protein called NgR1. Signalling is induced by a receptor complex containing the membrane proteins p75 and/or Troy and the LRR-protein Lingo1 [3–5]. An alternative Nogo-66 receptor is PirB. PirB is expressed at low or undetectable levels in many parts of the adult CNS, although its expression may be more prominent during neural development or after ischemia [6]. Activation of the signal transducer rho A and ROCK are downstream of the Nogo-66 interaction with NgR1 and mediate growth cone collapse and growth arrest of neurites [3,7]. Binding to NgR1 is enhanced to picomolar affinities by flanking sequences in particular in the Nogo-A specific domain [8].

Recent work has expanded our understanding of NgR1 regulation and function at two levels. Studies of the olfactory system development led to the identification of Cartilage Acidic Protein-1B (LOTUS) as an antagonist of Nogo-66 binding to NgR1 [9]*. The role of this endogenous antagonist for adult injury settings requires further study. Another line of work showed that NgR1 and the related protein NgR3 are not receptors solely for Nogo-A. They also participate in binding and axon growth inhibition by the chondroitin sulfate proteoglycans (CSPGs) known to be enriched in glial scars and perineuronal nets [10]*. Thus, oligodendrocyte-derived Nogo-A may share receptor mechanisms with other, astrocyte-derived inhibitors of nerve fiber growth and repair.

A second active region of Nogo-A is found in the N-terminal extracellular region (“Nogo-A d-20” or “amino-Nogo”)[5]. While its activity was known to depend on integrin engagement [11], its mechanism had been unclear until very recently. The sphingosine-1-phosphate receptor 2 (S1PR2) has now been identified as a specific binding partner and signal transducer for Nogo-A d-20 in neurons and Nogo-A responsive non-neuronal cells by a yeast 2-hybrid screen, co-immunoprecipitation, binding studies and in situ co-localization experiments [12]**. Nogo-A binding to this 7-transmembrane domain, G-protein coupled receptor activated the G-protein G-13, the rhoGEF LARG and rho A; all these steps are required for Nogo-A d-20 induced inhibition of neurite growth or fibroblast spreading. Whether NgR-1 and S1PR2 and their associated co-receptor proteins occur and function always in a complex or also independently, as well as a possible modulatory role of S1P on Nogo-A effects remain to be studied in detail. The role of three other recently identified Nogo-A binding proteins, GPCR- 50 [13], olfactomedin [14] and LRP1 [15] is currently unclear. However, since NgR1 binds several other ligands in addition to Nogo-66, a multisubunit receptor complex for Nogo-A with two (or more) binding subunits represents a highly attractive model for signal transduction with high specificity, analogous to what is known for e.g. neurotrophins, semaphorins or Wnt.

Nogo-A destabilizes the cytoskeleton and suppresses the cellular growth program

Growth cones collapse and neurite elongation stops upon contact with Nogo-A in a rho/ROCK dependent way. Interestingly, internalization of Nogo-A was shown to be required for these effects in growth cones of hippocampal neurons [16]. Integrin function is also affected by Nogo-A [11], and activation of integrins can overcome the Nogo-A mediated growth inhibition [17]*. The actin cytoskeleton-based lamellipodia and filopodia of growth cones are affected at an early stage of the collapse. Subsequently, internalized Nogo-A d-20 is transported retrogradely to neuronal cell bodies in signalling endosomes, a process leading to increased rho A and decreased phospho-CREB levels in cultured sensory neurons [16]. In hippocampal neurons Nogo-A was shown to decrease the activation of the key growth regulator mTOR [18].

Long-term effects of Nogo-A KO or neutralization showed sprouting of hippocampal axons and dendrites as well as up-regulation of a number of growth associated genes in the adult brain and spinal cord [19–21]*. Together with the findings on the role of Nogo-A as a negative controller of CNS plasticity summarized below, these results suggest a physiological role of Nogo-A as a factor controlling growth and plasticity in the adult CNS.

Suppression of Nogo-A/Nogo receptor signaling enhances repair after CNS injury

Spinal cord injuries affecting up to half of the spinal cord diameter or strokes destroying only part of the motor cortex often have a good prognosis with substantial spontaneous functional recovery in animals and humans. Compensatory sprouting of intact fiber systems and formation of new circuits including indirect “detour” pathways are currently emerging as important mechanisms underlying these functional recovery processes [22–24]. The factors which trigger and guide growing fibers, select and stabilize functionally meaningful connections and prune circuits leading to malfunction are almost entirely unknown, however. Neurite growth and regeneration can be stimulated by up-regulating the neuronal growth machinery, in particular via stimulation of the mTOR and the Stat3 pathways as shown mostly by anatomical data in rodents [25]. Overstimulation of sprouting by deletion of the important mTOR regulator PTEN can also lead to epilepsies and tumors, however [26–28]. In injury models, the functional consequences of unregulated stimulation of the neuronal growth program remain to be shown.

Many years of animal studies in a variety of models and species have shown that down-regulation or functional blockade of Nogo-A signalling leads to enhanced regenerative sprouting and fiber elongation and to enhanced compensatory fiber growth over distances exceeding those occurring spontaneously [2,28,29]. Interestingly, these anatomical changes were consistently associated with functional improvements in the absence of malfunctions, in different lesion models, species and using different ways to suppress Nogo function. These results suggest that temporarily restricted suppression of Nogo/Nogo receptor actions

enhance growth within a CNS microenvironment that still allows for some growth control and target selection.

The *methods used to suppress Nogo-A/Nogo receptor functions* in the adult, injured CNS include the intrathecal application of function blocking anti-Nogo-A antibodies, soluble NgR1-Fc fusion proteins, peptides blocking NgR1, immunization against Nogo or NgR1, or pharmacological blockers of rho or ROCK [28]. Interestingly, these acute interventions gave consistently stronger results than mice KO for Nogo-A, double KO for Nogo-A and MAG, or triple KO for Nogo-A, MAG and OMgp [5,30,31]. This suggests an important role of the compensatory up-regulation of other inhibitory factors as seen in the Nogo-A KO for ephrinA3, EphA4, Sema 4D and 3F and plexin B2 [32]. While compensatory and regenerative sprouting was consistently enhanced in different KO lines from different laboratories, the extent of growth and regeneration differed among the lines. The higher endogenous growth capacity of Sv129 strain neurons compared to C57Bl6 neurons in these mixed background lines may be an additional confounding factor [33].

Spinal cord injury

In rat, mouse and monkey models of large spinal cord injuries, suppression of Nogo-A/Nogo receptor signalling by many of the methods mentioned above resulted in enhanced anatomical plasticity and regrowth of functionally important fiber systems like the corticospinal tract or descending serotonin and dopamine fibers. Significant recovery of locomotion, balance, skilled stepping over irregular ladders and fine forepaw (rats, mice) and finger movements (monkeys) appeared within 2–4 weeks of the treatment [28,34]. Starting the anti-Nogo therapy within a few days after the lesion was more efficient than delayed treatments [35], although efficacy has been demonstrated with soluble NgR1-Fc fusion proteins in the chronic phase of spinal cord contusion, months after the trauma [36]. Serotonin fibers showed layer specific reinnervation patterns, and the decrease of postlesion spastic contractions after anti-Nogo-A antibodies in spinal cord injured rats suggest formation of functionally correct connections [37,38].

Stroke models

A high degree of functional restoration of skilled forelimb reaching in rats with large unilateral strokes or pyramidal tract lesions was observed with many interventions blocking Nogo-A or its receptor. Anatomically, corticospinal fibers from the intact side sprout across the midline e.g. of the spinal cord, retract their original arbor and functionally innervate the denervated spinal cord [23,39]. Interestingly, the functional and anatomical effects of intrathecal anti-Nogo-A antibodies were also observed in aged rats as well as after antibody application delayed up to 2 months [40,41]. Recovery of hand function and cortical map shifts were also observed in macaques following Nogo-A suppression [42]. Combined suppression of Nogo-A (by antibodies) and CSPGs (by chondroitinase) resulted in a higher degree of recovery of food pellet reaching in rats with large unilateral strokes [43].

Optic nerve lesions

In optic nerve lesions, NgR1 knock down or KO, Nogo-A neutralization or rho/ ROCK blockade leads to enhanced regenerative sprouting, but rarely to elongation over more than

1–2 mm [44]. In this system, however, the rapid death of retinal ganglion cells and the very low intrinsic growth potential of these neurons complicate the situation. High levels of CNTF, Stat 3 activation or PTEN deletion or combinations of these interventions led to a higher level of optic nerve axon regrowth, but also to many misdirected axons, including about half of the axons returning toward the retina [45,46]*. Only limited evidence exists up to now for functional benefits with innervation beyond the chiasm [47]. Of note, NgR1 decoy receptor therapy rescues retinal ganglion cell survival in a glaucoma model [48].

Multiple sclerosis

In the multiple sclerosis animal model of EAE, antibody mediated Nogo-A neutralization, systemic siRNA against Nogo-A, Nogo-A/B KO, or NgR1 deletion showed a beneficial effect on the clinical outcome [49–52]. Whether enhanced fiber growth, circuit plasticity and functional compensation and/or effects of myelin repair [53]* or immunological reactions are responsible for these functional improvements remains to be analysed.

Clinical studies

Early phase clinical trials are currently in progress for spinal cord injury, MS and amyotrophic lateral sclerosis (ALS) using intrathecal or systemic administration of function blocking anti-Nogo-A antibodies (see www.clinicaltrials.gov) [54]. Parallel studies with anti-MAG antibodies in human stroke recovery gave indications for improved walking speeds with therapy [55]. A trial using a function blocking NgR1-Fc protein is in preparation.

Nogo-A and NgR1 signaling titrates experience-dependent plasticity

It is abundantly clear that interruption of the Nogo-A to Nogo-66 Receptor pathway increases functional recovery after injury by a combination of neuronal plasticity, short range sprouting and axonal regeneration. The observation of anatomical rearrangements far from the injury site and by uninjured pathways raises the question of the natural role of this Nogo pathway for anatomical stability in the adult nervous system.

It is well appreciated that experience-dependent neural plasticity decreases during the transition from adolescence to adulthood, and a classic manifestation of this phenomenon is the closing of a critical period for robust ocular dominance plasticity in binocular cerebral cortex. Indeed, it has been shown that mice lacking either NgR1 or Nogo-A maintain adolescent critical period plasticity of the visual system into adulthood [56]. Since a similar phenotype of enhanced adult plasticity is also observed when CSPGs are digested [57], each of the major molecular categories limiting recovery from injury appear to play a natural role in stabilizing the adult central nervous system. A recent description of CSPGs as ligands for NgR1 and the related cell surface protein, NgR3, suggests that functional similarities may derive from mechanistic similarities in signal transduction [10].

Acute electrophysiological plasticity

The role of Nogo-A and NgR1 in limiting experience-dependent plasticity in adulthood might occur by either acute electrophysiological alterations and/or more chronic changes in anatomical stability. While the latter morphologic mechanism appears to parallel the role of

Nogo-A and NgR1 in the recovery from neurological trauma, there is also evidence for more acute regulation of synaptic transmission by these molecules. Studies of hippocampal slice long-term potentiation (LTP) demonstrated that administration of soluble Nogo-66 or OMgp altered synaptic plasticity, suppressing LTP and enhancing LTD [58,59]. These effects were dependent on the presence of NgR1 as a receptor. In separate studies, acute neutralization of endogenous Nogo-A or NgR1, or in vivo knock down of Nogo-A increased LTP [60,61]. Thus, acute modulation of synaptic plasticity may contribute to the ability of Nogo-A and NgR1 blockade to enhance recovery from CNS injury.

Stability of adult synaptic anatomy is dependent on Nogo-A and NgR1 signaling

A broad range of studies have implicated Nogo-A and NgR1 in determining the formation and stability of synaptic morphology over longer time scales. In hippocampal slices, post-synaptic dendritic spine architecture, as well as axonal length, was found to depend on Nogo-A and NgR1 signaling [20]. Interruption of Nogo-A or NgR1 expression produced more immature appearing dendritic spines. Genetic deletion of NgR1, 2 and 3 demonstrated a key role for these proteins as a brake on synaptogenesis both in vitro and in vivo during the initial stages of circuit formation [62]*. Interactions amongst the NgR family suggest partial redundancy in function, and this emphasizes the overlapping roles of CSPGs and myelin derived inhibitors in both limitation of neural plasticity and neural repair. Nogo-A regulation of synaptic development is not restricted to hippocampus. A recent study demonstrated that cerebellar Purkinje cell expression of Nogo-A limits both dendritic arborisation and synaptic inputs [63].

More recently, studies of Nogo-A and NgR1 regulation of synaptic stability have been extended via chronic time lapse in vivo imaging of anatomy [64]**. In mice lacking these molecules, synaptic structures were monitored for weeks in the living mouse. The dynamics of dendritic spines and axonal varicosities in the superficial layers of cerebral cortex was enhanced in mice lacking either NgR1 or Nogo-A. In fact, the stabilization of synaptic anatomy which normally occurs in late adolescence was not observed. In addition, the ability of altered sensory input to enhance anatomical turnover was shifted such that lesser degrees of vibrissal activity yielded greater degrees of anatomical change.

Behavioral consequences of Nogo-A and NgR1 signaling

Without Nogo-A or NgR1 signaling, adolescent critical periods for experience dependent plasticity remain open and the recovery from CNS injury is enhanced. Are these data associated with altered behaviour? One clue may come from the ability of high levels of neuronal excitation to suppress NgR1 levels [62,65], perhaps allowing anatomical plasticity to follow periods of hyperexcitation. In a study of mice expressing elevated levels of NgR1 [65], learning was intact but lasting memory formation was impaired. It was suggested that NgR1 down regulation is required to allow the anatomical rearrangement of synaptic connections underlying long term recall. The extinction of conditioned fear memories has been associated with the formation of new dendritic spines in prefrontal cortex [66]. Correspondingly, the enhanced cortical spine turnover of NgR1 null mice is associated with

enhanced fear extinction [64], suggesting the possibility of therapeutic blockade of Nogo-A or NgR1 to reduce posttraumatic stress disorder. It has been suggested that excess unregulated plasticity related to Nogo-A, myelin or NgR1 genetic variability could contribute to neuropsychiatric conditions such as schizophrenia [61,67–69].

Conclusions

The Nogo-A and NgR1 signalling cascade have been studied extensively with regard to neurological trauma. Blockade of these pathways leads to greater functional recovery through a combination of neural plasticity, sprouting and axonal regeneration. The benefits of interrupting Nogo-A or NgR1 are observed in a broad spectrum of preclinical models and are beginning clinical evaluation. Recent molecular studies have demonstrated a signalling pathway for a second domain of Nogo-A that involves the S1PR2 receptor. In addition, substantial overlaps between Nogo-A and CSPGS have been revealed for both signalling molecules and cellular consequences. The physiologic role of Nogo-A and NgR1 signalling has attracted much attention. This pathway limits adult brain plasticity at the level of acute electrophysiological modulation, shown most dramatically in the anatomical stability of synaptic morphology. Thus, releasing the brakes on anatomical plasticity, which are applied during the transition from adolescence to adulthood, provides an attractive pathway for neural repair therapeutics.

Acknowledgments

We acknowledge support from the National Institutes of Health and the Falk Medical Research Trust to S.M.S., and from the Swiss National Science Foundation and the Christopher and Dana Reeve Foundation to M.E.S.

References

1. Aguayo AJ, Rasminsky M, Bray GM, Carbonetto S, McKerracher L, Villegas-Perez MP, Vidal-Sanz M, Carter DA. Degenerative and regenerative responses of injured neurons in the central nervous system of adult mammals. *PhilTransRSocB*. 1991; 331:337–343.
2. Schwab ME. Nogo and axon regeneration. *Curr Opin Neurobiol*. 2004; 14(1):118–124. [PubMed: 15018947]
3. Nash M, Pribram H, Fournier AE, Jacobson C. Central nervous system regeneration inhibitors and their intracellular substrates. *Mol Neurobiol*. 2009; 40:224–235. [PubMed: 19763907]
4. Akbik F, Cafferty WBJ, Strittmatter SM. Myelin associated inhibitors: A link between injury-induced and experience-dependent plasticity. *Experimental Neurology*. 2012; 235(1):43–52. [PubMed: 21699896]
5. Schwab ME. Functions of nogo proteins and their receptors in the nervous system. *Nat Rev Neurosci*. 2010; 11(12):799–811. [PubMed: 21045861]
6. Gou X, Zhang Q, Xu N, Deng B, Wang H, Xu L, Wang Q. Spatio-temporal expression of paired immunoglobulin-like receptor-b in the adult mouse brain after focal cerebral ischaemia. *Brain Injury*. 2013; 27(11):1311–1315. [PubMed: 23927735]
7. Chivatakarn O, Kaneko S, He Z, Tessier-Lavigne M, Giger RJ. The nogo-66 receptor ngr1 is required only for the acute growth cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors. *J Neurosci*. 2007; 27(27):7117–7124. [PubMed: 17611264]
8. Huebner EA, Kim BG, Duffy PJ, Brown RH, Strittmatter SM. A multi-domain fragment of nogo-a protein is a potent inhibitor of cortical axon regeneration via nogo receptor 1. *Journal of Biological Chemistry*. 2011; 286(20):18026–18036. [PubMed: 21454605]

9. Sato Y, Iketani M, Kurihara Y, Yamaguchi M, Yamashita N, Nakamura F, Arie Y, Kawasaki T, Hirata T, Abe T, Kiyonari H, et al. Cartilage acidic protein-1b (lotus), an endogenous nogo receptor antagonist for axon tract formation. *Science*. 2011; 333(6043):769–773. [PubMed: 21817055] * This paper identifies cartilage acidic protein-1b (lotus) as a protein that competes with Nogo for binding to NgR1. This observation highlights the complex regulation of Nogo-A and NgR1 function in vivo.
10. Dickendesher TL, Baldwin KT, Mironova YA, Koriyama Y, Raiker SJ, Askew KL, Wood A, Geoffroy CG, Zheng B, Liepmann CD, Katagiri Y, et al. Ngr1 and ngr3 are receptors for chondroitin sulfate proteoglycans. *Nat Neurosci*. 2012; 15(5):703–712. [PubMed: 22406547] * Using double and triple KO mice for the Nogo-A receptor NgR1 and its related family members NgR2 and 3, the study shows that NgR1 and 3, but not 2 also bind CSPGs. NgR1+3 KOs show enhanced regeneration of the lesioned optic nerve. The NgR family of receptors thus interact with two unrelated ligands, Nogo-A and CSPGs, both of which exert neurite growth inhibitory functions.
11. Hu F, Strittmatter SM. The n-terminal domain of nogo-a inhibits cell adhesion and axonal outgrowth by an integrin-specific mechanism. *J Neurosci*. 2008; 28(5):1262–1269. [PubMed: 18234903]
12. Kempf A, Tews B, Arzt ME, Weinmann O, Obermair FJ, Pernet V, Zagrebelsky M, Delekate A, Iobbi C, Zemmar A, Ristic Z, Gullo M, Spies P, Dodd D, Gygax D, Korte M, Schwab ME. The sphingolipid receptor s1pr2 is a receptor for nogo-a repressing synaptic plasticity. *PLOS Biol*. 2013; 12(1):e1001763. [PubMed: 24453941] ** The functional receptor for the N-terminal Nogo-A active site has long remained elusive. This study identifies S1PR2 as a high affinity, signal transducing Nogo-A receptor that activates RhoA via G-13 and the RhoGEF LARG. Knock down or pharmacological blockade of S1PR2 suppress the effects of Nogo-A on neurite growth and hippocampal LTP.
13. Grünewald E, Kinnell HL, Porteous DJ, Thomson PA. Gpr50 interacts with neuronal nogo-a and affects neurite outgrowth. *Molecular and Cellular Neuroscience*. 2009; 42(4):363–371. [PubMed: 19699797]
14. Nakaya N, Sultana A, Lee H-S, Tomarev SI. Olfactomedin 1 interacts with the nogo a receptor complex to regulate axon growth. *Journal of Biological Chemistry*. 2012; 287(44):37171–37184. [PubMed: 22923615]
15. Stiles TL, Dickendesher TL, Gaultier A, Fernandez-Castaneda A, Mantuano E, Giger RJ, Gonias SL. Ldl receptor-related protein-1 is a sialic-acid-independent receptor for myelin-associated glycoprotein that functions in neurite outgrowth inhibition by mag and cns myelin. *Journal of Cell Science*. 2013; 126(1):209–220. [PubMed: 23132925]
16. Joset A, Dodd DA, Halegoua S, Schwab ME. Pincher-generated nogo-a endosomes mediate growth cone collapse and retrograde signaling. *J Cell Biol*. 2010; 188(2):271–285. [PubMed: 20083601]
17. Tan CL, Kwok JCF, Patani R, French-Constant C, Chandran S, Fawcett JW. Integrin activation promotes axon growth on inhibitory chondroitin sulfate proteoglycans by enhancing integrin signaling. *The Journal of Neuroscience*. 2011; 31(17):6289–6295. [PubMed: 21525268] * Integrins have been shown to be involved in the neurite growth inhibitory effects of Nogo-A. Here, activation of integrins by Mn++ or a specific activating antibody is shown to result in significant neurite outgrowth in spite of the presence of Nogo-A or the inhibitory CSPG aggrecan.
18. Peng X, Kim J, Zhou Z, Fink DJ, Mata M. Neuronal nogo-a regulates glutamate receptor subunit expression in hippocampal neurons. *Journal of Neurochemistry*. 2011; 119(6):1183–1193. [PubMed: 21985178]
19. Montani L, Gerrits B, Gehrig P, Kempf A, Dimou L, Wollscheid B, Schwab ME. Neuronal nogo-a modulates growth cone motility via rho-gtp/limk1/cofilin in the unlesioned adult nervous system. *J Biol Chem*. 2009; 284(16):10793–10807. [PubMed: 19208621]
20. Zagrebelsky M, Schweigreiter R, Bandtlow CE, Schwab ME, Korte M. Nogo-a stabilizes the architecture of hippocampal neurons. *J Neurosci*. 2010; 30(40):13220–13234. [PubMed: 20926648] * Postnatal hippocampal slices in organotypic cultures reach a mature stage in vitro within 3 weeks. After that time, anti-Nogo-A or anti-NgR1 antibodies were added in this study, or Nogo-A was knocked down in pyramidal cells. CA3 pyramidal cell axons sprouted massively,

dendrites pruned proximally and sprouted distally, and synaptic spine shapes shifted to immature stages. The results demonstrate an important role of Nogo-A/NGR1 for the stabilization of the hippocampal architecture.

21. Craveiro LM, Hakkoum D, Weinmann O, Montani L, Stoppini L, Schwab ME. Neutralization of the membrane protein nogo-a enhances growth and reactive sprouting in established organotypic hippocampal slice cultures. *Eur J Neurosci.* 2008; 28(9):1808–1824. [PubMed: 18973596]
22. Bareyre FM, Kerschensteiner M, Raineteau O, Mettenleiter TC, Weinmann O, Schwab ME. The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. *Nat Neurosci.* 2004; 7:269–277. [PubMed: 14966523]
23. Raineteau O, Schwab ME. Plasticity of motor systems after incomplete spinal cord injury. *Nat Rev Neurosci.* 2001; 2:263–274. [PubMed: 11283749]
24. van den Brand R, Heutschi J, Barraud Q, DiGiovanna J, Bartholdi K, Huerlimann M, Friedli L, Vollenweider I, Morad EM, Duis S, Dominici N, et al. Restoring voluntary control of locomotion after paralyzing spinal cord injury. *Science.* 2012; 336(6085):1182–1185. [PubMed: 22654062]
25. Liu K, Tedeschi A, Park KK, He Z. Neuronal intrinsic mechanisms of axon regeneration. *Annual Review of Neuroscience.* 2011; 34(1):131–152.
26. Pun Raymond YK, Rolle Isaiah J, LaSarge Candi L, Hosford Bethany E, Rosen Jules M, Uhl Juli D, Schmeltzer Sarah N, Faulkner C, Bronson Stefanie L, Murphy Brian L, Richards David A, et al. Excessive activation of mtor in postnatally generated granule cells is sufficient to cause epilepsy. *Neuron.* 2012; 75(6):1022–1034. [PubMed: 22998871]
27. Akhavan D, Cloughesy TF, Mischel PS. Mtor signaling in glioblastoma: Lessons learned from bench to bedside. *Neuro-Oncology.* 2010; 12(8):882–889. [PubMed: 20472883]
28. Zorner B, Schwab ME. Anti-nogo on the go: From animal models to a clinical trial. *Ann N Y Acad Sci.* 2010; 1198(Suppl 1):E22–E34. [PubMed: 20590535]
29. Cafferty WB, McGee AW, Strittmatter SM. Axonal growth therapeutics: Regeneration or sprouting or plasticity? *Trends Neurosci.* 2008; 31(5):215–220. [PubMed: 18395807]
30. Cafferty WB, Duffy P, Huebner E, Strittmatter SM. Mag and omgp synergize with nogo-a to restrict axonal growth and neurological recovery after spinal cord trauma. *J Neurosci.* 2010; 30(20):6825–6837. [PubMed: 20484625]
31. Lee JK, Chow R, Xie F, Chow SY, Tolentino KE, Zheng B. Combined genetic attenuation of myelin and semaphorin-mediated growth inhibition is insufficient to promote serotonergic axon regeneration. *J Neurosci.* 2010; 30(32):10899–10904. [PubMed: 20702718]
32. Kempf A, Montani L, Petrinovic MM, Schroeter A, Weinmann O, Patrignani A, Schwab ME. Upregulation of axon guidance molecules in the adult central nervous system of nogo-a knockout mice restricts neuronal growth and regeneration. *European Journal of Neuroscience.* 2013; 38(11):3567–3579. [PubMed: 24103058]
33. Dimou L, Schnell L, Montani L, Duncan C, Simonen M, Schneider R, Liebscher T, Gulló M, Schwab ME. Nogo-a-deficient mice reveal strain-dependent differences in axonal regeneration. *J Neurosci.* 2006; 26:5591–5603. [PubMed: 16723516]
34. Freund P, Schmidlin E, Wannier T, Bloch J, Mir A, Schwab ME, Rouiller EM. Anti-nogo-a antibody treatment promotes recovery of manual dexterity after unilateral cervical lesion in adult primates—re-examination and extension of behavioral data. *Eur J Neurosci.* 2009; 29(5):983–996. [PubMed: 19291225]
35. Gonzenbach RR, Zorner B, Schnell L, Weinmann O, Mir A, Schwab ME. Delayed anti-nogo-a antibody application after spinal cord injury shows progressive loss of responsiveness. *J Neurotrauma.* 2012; 29:567–578. [PubMed: 21815784]
36. Wang X, Duffy P, McGee AW, Hasan O, Gould G, Tu N, Harel NY, Huang Y, Carson RE, Weinzimmer D, Ropchan J, et al. Recovery from chronic spinal cord contusion after nogo receptor intervention. *Ann Neurol.* 2011; 70(5):805–821. [PubMed: 22162062]
37. Mullner A, Gonzenbach RR, Weinmann O, Schnell L, Liebscher T, Schwab ME. Lamina-specific restoration of serotonergic projections after nogo-a antibody treatment of spinal cord injury in rats. *Eur J Neurosci.* 2008; 27(2):326–333. [PubMed: 18215231]

38. Gonzenbach RR, Gasser P, Zorner B, Hochreutener E, Dietz V, Schwab ME. Nogo-a antibodies and training reduce muscle spasms in spinal cord-injured rats. *Ann Neurol*. 2010; 68(1):48–57. [PubMed: 20582944]
39. Lindau NT, Bänninger BJ, Gullo M, Good NA, Bachmann LC, Starkey LM, Schwab ME. Rewiring of the corticospinal tract in the adult rat after unilateral stroke and anti-nogo-a therapy. *Brain*. 2013
40. Tsai SY, Papadopoulos CM, Schwab ME, Kartje GL. Delayed anti-nogo-a therapy improves function after chronic stroke in adult rats. *Stroke*. 2011; 42(1):186–190. [PubMed: 21088244]
41. Markus TM, Tsai SY, Bollnow MR, Farrer RG, O'Brien TE, Kindler-Baumann DR, Rausch M, Rudin M, Wiessner C, Mir AK, Schwab ME, et al. Recovery and brain reorganization after stroke in adult and aged rats. *Ann Neurol*. 2005; 58(6):950–953. [PubMed: 16315284]
42. Wyss AF, Hamadjida A, Savidan J, Liu Y, Bashir S, Mir A, Schwab ME, Rouiller EM, Belhaj-Saif A. Long-term motor cortical map changes following unilateral lesion of the hand representation in the motor cortex in macaque monkeys showing functional recovery of hand functions. *Restorative Neurology and Neuroscience*. 2013 in press.
43. Zhao R-R, Andrews MR, Wang D, Warren P, Gullo M, Schnell L, Schwab ME, Fawcett JW. Combination treatment with anti-nogo-a and chondroitinase abc is more effective than single treatments at enhancing functional recovery after spinal cord injury. *European Journal of Neuroscience*. 2013; 38(6):2946–2961. [PubMed: 23790207]
44. Pernet V, Schwab ME. The role of nogo-a in axonal plasticity, regrowth and repair. *Cell Tissue Res*. 2012; 349:97–104. [PubMed: 22588543]
45. Pernet V, Joly S, Dalkara D, Jordi N, Schwarz O, Christ F. Long-distance axonal regeneration induced by cntf gene transfer is impaired by axonal misguidance in the injured adult optic nerve. *Neurobiol Dis*. 2013; 51:202–213. [PubMed: 23194670] * See Ref. 46
46. Luo X, Salgueiro Y, Beckerman SR, Lemmon VP, Tsoulfas P, Park KK. Three-dimensional evaluation of retinal ganglion cell axon regeneration and pathfinding in whole mouse tissue after injury. *Experimental Neurology*. 2013; 247(0):653–662. [PubMed: 23510761] * After optic nerve injury, the poor growth and survival capacity of retinal ganglion cells greatly impairs any repair attempt. Application of CNTF via Muller cells (Ref. 45) or simultaneous activation of mTOR (by PTEN deletion) and the Stat-3 pathways massively stimulated regenerative sprouting in the injured nerve. Microscopy of cleared whole nerve preparations and single fiber reconstruction showed a dramatic number of misguided fibers; many fibers stopped before reaching the chiasm or turned back towards the lesion site, few fibers entered the contralateral optic nerve or the ipsilateral optic tract. These results point to the absence of guidance cues and the presence of repulsors as an important additional problem for optic nerve regeneration.
47. de Lima S, Koriyama Y, Kurimoto T, Oliveira JT, Yin Y, Li Y, Gilbert H-Y, Fagiolini M, Martinez AMB, Benowitz L. Full-length axon regeneration in the adult mouse optic nerve and partial recovery of simple visual behaviors. *Proceedings of the National Academy of Sciences*. 2012; 109(23):9149–9154.
48. Fu QL, Liao XX, Li X, Chen D, Shi J, Wen W, Lee DH, So KF. Soluble nogo-66 receptor prevents synaptic dysfunction and rescues retinal ganglion cell loss in chronic glaucoma. *Invest Ophthalmol Vis Sci*. 2011; 52(11):8374–8380. [PubMed: 21948553]
49. Yang Y, Liu Y, Wei P, Peng H, Winger R, Hussain RZ, Ben L-H, Cravens PD, Gocke AR, Puttaparthi K, Racke MK, et al. Silencing nogo-a promotes functional recovery in demyelinating disease. *Annals of Neurology*. 2010; 67(4):498–507. [PubMed: 20437585]
50. Rudick RA, Mi S, Sandrock AW. Lingo-1 antagonists as therapy for multiple sclerosis: In vitro and in vivo evidence. *Expert Opinion on Biological Therapy*. 2008; 8(10):1561–1570. [PubMed: 18774923]
51. Petratos S, Ozturk E, Azari MF, Kenny R, Young Lee J, Magee KA, Harvey AR, McDonald C, Taghian K, Moussa L, Mun Aui P, et al. Limiting multiple sclerosis related axonopathy by blocking nogo receptor and crmp-2 phosphorylation. *Brain*. 2012; 135(6):1794–1818. [PubMed: 22544872]
52. Karnezis T, Mandemakers W, McQualter JL, Zheng B, Ho PP, Jordan KA, Murray BM, Barres B, Tessier-Lavigne M, Bernard CCA. The neurite outgrowth inhibitor nogo a is involved in autoimmune-mediated demyelination. *Nature Neurosci*. 2004; 7:736–744. [PubMed: 15184901]

53. Chong SYC, Rosenberg SS, Fancy SPJ, Zhao C, Shen Y-AA, Hahn AT, McGee AW, Xu X, Zheng B, Zhang LI, Rowitch DH, et al. Neurite outgrowth inhibitor nogo-a establishes spatial segregation and extent of oligodendrocyte myelination. *Proceedings of the National Academy of Sciences*. 2012; 109(4):1299–1304. * Roles of Nogo-A for the development of oligodendrocytes were largely unknown so far. This study shows that oligodendrocyte processes undergo repulsive interactions during myelin formation, especially at the future site of Ranvier nodes. Nogo-A plays a crucial role; its deletion leads to exuberant and overlapping myelin formation.
54. Abel R, Baron HC, Casha S, Harms J, Hurlbert J, Kucher K, Maier D, Thietje R, Weidner N, Curt A. Therapeutic anti-nogo-a antibodies in acute spinal cord injury: Safety and pharmacokinetic data from an ongoing first-in-human trial. ISCOS meeting. 2011 2011.
55. Cramer SC, Abila B, Scott NE, Simeoni M, Enney LA. Safety, pharmacokinetics, and pharmacodynamics of escalating repeat doses of gsk249320 in patients with stroke. *Stroke*. 2013; 44(5):1337–1342. [PubMed: 23471268]
56. McGee AW, Yang Y, Fischer QS, Daw NW, Strittmatter SM. Experience-driven plasticity of visual cortex limited by myelin and nogo receptor. *Science*. 2005; 309(5744):2222–2226. [PubMed: 16195464]
57. Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L. Reactivation of ocular dominance plasticity in the adult visual cortex. *Science*. 2002; 298(5596):1248–1251. [PubMed: 12424383]
58. Raiker SJ, Lee H, Baldwin KT, Duan Y, Shrager P, Giger RJ. Oligodendrocyte-myelin glycoprotein and nogo negatively regulate activity-dependent synaptic plasticity. *J Neurosci*. 2010; 30(37):12432–12445. [PubMed: 20844138]
59. Lee H, Raiker SJ, Venkatesh K, Geary R, Robak LA, Zhang Y, Yeh HH, Shrager P, Giger RJ. Synaptic function for the nogo-66 receptor ngr1: Regulation of dendritic spine morphology and activity-dependent synaptic strength. *J Neurosci*. 2008; 28(11):2753–2765. [PubMed: 18337405]
60. Delekate A, Zagrebelsky M, Kramer S, Schwab ME, Korte M. Nogo restricts synaptic plasticity in the adult hippocampus on a fast time scale. *Proc Natl Acad Sci U S A*. 2011; 108(6):2569–2574. [PubMed: 21262805]
61. Tews B, Schöning K, Arzt ME, Clementi S, Rioult-Pedotti M-S, Zemmar A, Berger SM, Schneider M, Enkel T, Weinmann O, Kasper H, et al. Synthetic microRNA-mediated downregulation of nogo-a in transgenic rats reveals its role as regulator of synaptic plasticity and cognitive function. *Proceedings of the National Academy of Sciences*. 2013; 110(16):6583–6588.
62. Wills ZP, Mandel-Brehm C, Mardinly AR, McCord AE, Giger RJ, Greenberg ME. The nogo receptor family restricts synapse number in the developing hippocampus. *Neuron*. 2012; 73(3):466–481. [PubMed: 22325200] * The family of NgR1 related proteins is shown to play a critical and partial redundant role in synapse formation using single and multiple gene knockout techniques.
63. Petrinovic MM, Hourez R, Aloy EM, Dewarrat G, Gall D, Weinmann O, Gaudias J, Bachmann LC, Schiffmann SN, Vogt KE, Schwab ME. Neuronal nogo-a negatively regulates dendritic morphology and synaptic transmission in the cerebellum. *Proc Natl Acad Sci U S A*. 2013; 110(3):1083–1088. [PubMed: 23277570]
64. Akbik FV, Bhagat SM, Patel PR, Cafferty WB, Strittmatter SM. Anatomical plasticity of adult brain is titrated by nogo receptor 1. *Neuron*. 2013; 77(5):859–866. [PubMed: 23473316] ** The stability of dendritic spine and axonal varicosities was assessed as a function of NgR1 genotype by in vivo time lapse imaging in cerebral cortex. Young adolescent mice have rapid turnover of these anatomical features, but stabilization during the transition to adulthood occurs only when both NgR1 and Nogo-A are present.
65. Karlen A, Karlsson TE, Mattsson A, Lundstromer K, Codeluppi S, Pham TM, Backman CM, Ogren SO, Aberg E, Hoffman AF, Sherling MA, et al. Nogo receptor 1 regulates formation of lasting memories. *Proc Natl Acad Sci U S A*. 2009; 106(48):20476–20481. [PubMed: 19915139]
66. Lai CS, Franke TF, Gan WB. Opposite effects of fear conditioning and extinction on dendritic spine remodelling. *Nature*. 2012; 483(7387):87–91. [PubMed: 22343895]
67. Budel S, Padukkavidana T, Liu BP, Feng Z, Hu F, Johnson S, Lauren J, Park JH, McGee AW, Liao J, Stillman A, et al. Genetic variants of nogo-66 receptor with possible association to

schizophrenia block myelin inhibition of axon growth. *J Neurosci.* 2008; 28(49):13161–13172. [PubMed: 19052207]

68. Willi R, Schwab ME. Nogo and nogo receptor: Relevance to schizophrenia? *Neurobiology of disease.* 2013; 54:150–157. [PubMed: 23369871]
69. Willi R, Weinmann O, Winter C, Klein J, Sohr R, Schnell L, Yee BK, Feldon J, Schwab ME. Constitutive genetic deletion of the growth regulator nogo-a induces schizophrenia-related endophenotypes. *J Neurosci.* 2010; 30(2):556–567. [PubMed: 20071518]

Highlights

- Nogo-A limits neural repair and recovery after adult CNS injuries
- NgR1 and S1PR2 are receptors for different domains of Nogo-A
- Nogo-A and NgR1 limit experience-dependent neural plasticity
- Nogo-A and NgR1 stabilize synaptic, dendritic and axonal anatomy in the adult CNS

Figure 1. Molecular Mechanisms Related to Nogo-A Signaling

The schematic illustrates the two growth inhibiting domains of Nogo-A, the 20 region and the Nogo-66 region. The two hydrophobic (HP1, HP2) segments are highlighted, as well as two adjacent regions (light green) that cooperate with Nogo-66 activity. The 20 region interacts with S1PR2, and the Nogo-66 region interacts with NgR1, and both can couple to RhoA and Rho-Associated Kinase (ROCK) signaling. Additional recent findings demonstrate that chondroitin sulfate proteoglycans (CSPGs) can inhibit growth via both NgR1 and NgR3, and that the LOTUS protein antagonizes Nogo-66 signaling. Further discussion and references are provided in the text.

Figure 2. Cellular Mechanisms of Neural Repair Limited by Nogo-A and NgR1

Injuries to the central nervous system of traumatic, ischemic or other etiology typically damage certain axonal pathways but spare parallel pathways. Recovery and repair can be supported by a range of cellular events, here grouped into three main mechanisms. The cut axon can grow back over long distances by regeneration, or uninjured and injured fibers that are rostral and caudal to the injury can sprout to form new connections, or plastic changes of presynaptic and postsynaptic connections throughout the nervous system. Data show that Nogo-A and NgR1 limit all three of these mechanisms, and blockade of their action supports repair and recovery. Further discussion and references are provided in the text.